A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06618287
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986507 — DRUG
    Specified dose on specified days
  • Osimertinib — DRUG
    Specified dose on specified days
  • Pembrolizumab — DRUG
    Specified dose on specified days
  • Nivolumab — DRUG
    Specified dose on specified days
  • Pumitamig — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Key Dates

Start date
Feb 4, 2025
Status verified
May 2026
Primary completion
Feb 26, 2031
Completion
Feb 26, 2031

Study Design

Enrollment
416 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Group A
  • Experimental: Group B
  • Experimental: Group C
  • Experimental: Group D
  • Experimental: Group E

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to 3 years ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (14)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
Aakash Desai, Site 0066
919-525-0054
University of Miami Hospital and Clinics, Sylvester Cancer CenterMiamiFlorida33136
Gilberto DE LIMA LOPES JUNIOR, Site 0009
305-243-1086
Local Institution - 0125MaywoodIllinois60153
Site 0125
Local Institution - 0065Iowa CityIowa52242
Site 0065
John Theurer Cancer Center at Hackensack University Medical CenterHackensackNew Jersey07601
Martin Gutierrez, Site 0010
551-996-5863
Cleveland ClinicClevelandOhio44195
Khaled Hassan, Site 0029
734-615-2939
Local Institution - 0102ColumbusOhio43212
Site 0102
Local Institution - 0052PortlandOregon97239
Site 0052
Local Institution - 0090PortlandOregon97239
Site 0090
Local Institution - 0134PortlandOregon97225
Site 0134
Local Institution - 0014PittsburghPennsylvania15232-
Local Institution - 0103KnoxvilleTennessee37920
Site 0103
NEXT Oncology - IrvingIrvingTexas75039
Michael Song, Site 0092
210-580-9500
Swedish Medical CenterSeattleWashington98104
Siddhartha Devarakonda, Site 0012
206-386-2457

Find similar trials in Birmingham, AL

By condition
Breast cancerLung cancer
By specialty
OncologyBreast oncologyWomen's healthLung oncologyLung disease
By research site
University of Alabama at Birmingham· Birmingham, ALUniversity of Miami Hospital and Clinics, Sylvester Cancer Center· Miami, FLLocal Institution - 0125· Maywood, ILLocal Institution - 0065· Iowa City, IAJohn Theurer Cancer Center at Hackensack University Medical Center· Hackensack, NJCleveland Clinic· Cleveland, OH

Related Studies